FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283268669> ?p ?o ?g. }

• W4283268669 abstract "Objective Atezolizumab is becoming a significant therapy for non-small cell lung cancer (NSCLC), but its efficacy needs to be further improved. The aims of this study are to clarify the potency of atezolizumab-based therapy in advanced NSCLC patients with different clinical and molecular features, and to choose a better therapeutic regimen of atezolizumab to achieve more precise treatment in immunotherapy. Methods Randomized clinical trials (RCTs) in the Cochrane Library, PubMed, Embase Science Direct, and Google Scholar, together with major oncology conferences that compared atezolizumab with chemotherapy-based treatment for individuals with advanced NSCLC published prior to February 2022, were searched. Studies, bias risk assessment, and data extraction were selected by two independent authors. We extracted the basic features of the included studies, together with the 95% confidence interval (CI) and hazard ratios (HRs), from all patients and subgroups. The combined treatment data were assessed using the inverse variance weighting method. Results Seven RCTs including 4,859 patients were included. Our meta-analysis findings indicated that atezolizumab substantially enhanced OS (HR 0.82; 95% CI, 0.77–0.88; p &lt; 0.00001) and PFS (HR 0.72; 95% CI, 0.61–0.85; p &lt; 0.0001) in patients with advanced NSCLC compared with chemotherapy-based treatment. Atezolizumab substantially enhanced OS in patients aged &lt;65 years old and 65–74 years old, those with wild-type EGFR, those without liver metastases, active or previous smokers, white patients and those with TC3 or IC3, TC2/3 or IC2/3, TC1/2/3 or IC1/2/3, and TC0 and IC0, but not in patients aged ≥75 years, never smokers, those with liver metastases, those with EGFR mutant, Asians, Black or African Americans, or those with TC1/2 or IC1/2. Patients with advanced NSCLC who received atezolizumab showed OS improvement regardless of sex (male or female), histological type (non-squamous or squamous NSCLC), performance status (0 or 1), and line of treatment (1st-line therapy or ≥2nd-line therapy). Subgroup analysis revealed that male individuals, those with non-squamous NSCLC, those with PS 1, active or previous smokers, and those with wild-type EGFR, TC3 or IC3, and TC1/2/3 or IC1/2/3 achieved OS benefit from atezolizumab treatment not related to the treatment line and treatment regimen. Conclusions Age group, smoking history, liver metastasis status, EGFR mutation status, race, and PD-L1 expression can be used to predict the potency of atezolizumab and provide a better treatment regimen for patients with advanced NSCLC to achieve accurate and personalized treatment." @default.
• W4283268669 created "2022-06-23" @default.
• W4283268669 creator A5013652689 @default.
• W4283268669 creator A5068377419 @default.
• W4283268669 creator A5081625307 @default.
• W4283268669 date "2022-06-21" @default.
• W4283268669 modified "2023-09-30" @default.
• W4283268669 title "Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis" @default.
• W4283268669 cites W1538902372 @default.
• W4283268669 cites W1573433003 @default.
• W4283268669 cites W1917614082 @default.
• W4283268669 cites W1994993231 @default.
• W4283268669 cites W2000905326 @default.
• W4283268669 cites W2008534009 @default.
• W4283268669 cites W2009519656 @default.
• W4283268669 cites W2034751554 @default.
• W4283268669 cites W2038982031 @default.
• W4283268669 cites W2049553585 @default.
• W4283268669 cites W2124427232 @default.
• W4283268669 cites W2127036601 @default.
• W4283268669 cites W2131876608 @default.
• W4283268669 cites W2152027636 @default.
• W4283268669 cites W2171176090 @default.
• W4283268669 cites W2210453860 @default.
• W4283268669 cites W2251438188 @default.
• W4283268669 cites W2288894747 @default.
• W4283268669 cites W2288908606 @default.
• W4283268669 cites W2291298003 @default.
• W4283268669 cites W2293531514 @default.
• W4283268669 cites W2345664439 @default.
• W4283268669 cites W2435563082 @default.
• W4283268669 cites W2464190812 @default.
• W4283268669 cites W2486637311 @default.
• W4283268669 cites W2497746146 @default.
• W4283268669 cites W2518536270 @default.
• W4283268669 cites W2560367415 @default.
• W4283268669 cites W2567564314 @default.
• W4283268669 cites W2601854298 @default.
• W4283268669 cites W2607288266 @default.
• W4283268669 cites W2610994169 @default.
• W4283268669 cites W2625684877 @default.
• W4283268669 cites W2731921472 @default.
• W4283268669 cites W2745683917 @default.
• W4283268669 cites W2745874962 @default.
• W4283268669 cites W2746430748 @default.
• W4283268669 cites W2765672396 @default.
• W4283268669 cites W2766425839 @default.
• W4283268669 cites W2767896186 @default.
• W4283268669 cites W2777461561 @default.
• W4283268669 cites W2783897381 @default.
• W4283268669 cites W2797780288 @default.
• W4283268669 cites W2803847828 @default.
• W4283268669 cites W2805354595 @default.
• W4283268669 cites W2808333550 @default.
• W4283268669 cites W2809937927 @default.
• W4283268669 cites W2884928681 @default.
• W4283268669 cites W2885658600 @default.
• W4283268669 cites W2886963239 @default.
• W4283268669 cites W2894023816 @default.
• W4283268669 cites W2895006950 @default.
• W4283268669 cites W2897523860 @default.
• W4283268669 cites W2900778493 @default.
• W4283268669 cites W2903663678 @default.
• W4283268669 cites W2906071128 @default.
• W4283268669 cites W2907028960 @default.
• W4283268669 cites W2911188335 @default.
• W4283268669 cites W2914335731 @default.
• W4283268669 cites W2924289105 @default.
• W4283268669 cites W2944860885 @default.
• W4283268669 cites W2945430578 @default.
• W4283268669 cites W2945998739 @default.
• W4283268669 cites W2946386783 @default.
• W4283268669 cites W2948936033 @default.
• W4283268669 cites W2972212968 @default.
• W4283268669 cites W2972582992 @default.
• W4283268669 cites W2985170860 @default.
• W4283268669 cites W2995123342 @default.
• W4283268669 cites W2999281781 @default.
• W4283268669 cites W3000339487 @default.
• W4283268669 cites W3002314881 @default.
• W4283268669 cites W3003299955 @default.
• W4283268669 cites W3008898612 @default.
• W4283268669 cites W3017322331 @default.
• W4283268669 cites W3023823544 @default.
• W4283268669 cites W3044008499 @default.
• W4283268669 cites W3091399767 @default.
• W4283268669 cites W3110814768 @default.
• W4283268669 cites W3115349904 @default.
• W4283268669 cites W3128409629 @default.
• W4283268669 cites W3160380101 @default.
• W4283268669 cites W3182948012 @default.
• W4283268669 cites W3183409909 @default.
• W4283268669 cites W3201990859 @default.
• W4283268669 cites W3204380660 @default.
• W4283268669 cites W4200134914 @default.
• W4283268669 cites W4211037971 @default.
• W4283268669 cites W4221134810 @default.
• W4283268669 doi "https://doi.org/10.3389/fimmu.2022.909027" @default.
• W4283268669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35799785" @default.
• W4283268669 hasPublicationYear "2022" @default.

• next